WO 2005/053739 PCT/GB2004/005008 75

1	Cla	ims
-		

2

7

8

9

10

11

3 1. Use of

4 (a) a specific binding member which binds to a 5 cell death receptor or a nucleic acid encoding

6 said binding member and

> (b) a chemotherapeutic agent, wherein the chemotherapeutic agent is a topoisomerase inhibitor or a thymidylate synthase inhibitor in the preparation of a medicament for the treatment of a cancer, wherein the cancer is a

12 13

The use according to claim 1 wherein the cancer 14 2. 15 is one or more of colorectal, breast, ovarian, cervical, gastric, lung, liver, skin and 16 17 myeloid (e.g. bone marrow) cancer.

cancer associated with a p53 mutation.

18

The use according to claim 1 or claim 2 wherein 19 3. 20 the death receptor is FAS.

21

The use according to claim 1 or claim 2 wherein 22 4.23 the binding member is an antibody or a fragment thereof. 24

25

The use according to any one of the preceding 26 5. 27 claims wherein the binding member is the anti-28 FAS antibody CH11.

29

30 б. The use according to any one of the preceding 31 claims wherein said chemotherapeutic agent is an antifolate thymidylate synthase inhibitor or 32

WO 2005/053739

PCT/GB2004/005008

76

1 a topoisomerase-I inhibitor.

2

7. The use according to any one of the preceding claims, wherein said chemotherapeutic agent is TDX or irinotecan (CPT-11).

6

7 8. The use according to any one of the preceding 8 claims, wherein said specific binding member 9 and chemotherapeutic agent are provided in concentrations sufficient to produce an RI of greater than 1.5.

12

A method of killing cancer cells having a p53 13 9. mutation, said method comprising the separate, 14 sequential or simultaneous administration to 15 said cells of a therapeutically effective 16 amount of a) a specific binding member which 17 binds to a cell death receptor or a nucleic 18 acid encoding said binding member and (b) a 19 chemotherapeutic agent, wherein said 20 chemotherapeutic agent is a topoisomerase 21 inhibitor or a thymidylate synthase inhibitor. 22

23

A method of treating cancer cells having a p53 10. 24 mutation comprising the separate, sequential or 25 simultaneous administration to a mammal in need 26 thereof of a therapeutically effective amount 27 of a) a specific binding member which binds to 28 a cell death receptor or a nucleic acid 29 encoding said binding member and (b) a 30 chemotherapeutic agent, wherein said 31 32 chemotherapeutic agent is a topoisomerase

WO 2005/053739 PCT/GB2004/005008 77

1 inhibitor or a thymidylate synthase inhibitor. 2 3 4 11. The method according to claim 9 or claim 10 5 wherein the cancer is one or more of colorectal, breast , ovarian, cervical, 6 7 gastric, lung, liver, skin and myeloid (e.g. 8 bone marrow) cancer. 9 The method according to claim 9, 10 or 11 10 12. 11 wherein the binding member is an antibody or a 12 fragment thereof. 13 The method according to any one of claims 9 to 14 13. 15 12 wherein the death receptor is FAS. 16 17 14. The method according to any one of claims 9 to 18 13 wherein the binding member is the anti-FAS 19 antibody CH11. 20 The method according to any one of claims 9 to 21 15. 22 14 wherein said chemotherapeutic agent is an 23 antifolate thymidylate synthase inhibitor or a topoisomerase-I inhibitor. 24 25 The method according to any one of claims 9 to 26 16. 27 15 wherein, wherein said chemotherapeutic agent 28 is TDX or irinotecan (CPT-11). 29 The method according to claim 16 wherein said 30 17. 31 specific binding member and chemotherapeutic 32 agent are provided in concentrations sufficient

PCT/GB2004/005008

to produce an RI of greater than 1.5.

2

WO 2005/053739

A product comprising a) a specific binding 3 18. member which binds to a cell death receptor or 4 a nucleic acid encoding said binding member and 5 (b) a chemotherapeutic agent as a combined 6 preparation for the simultaneous, separate or 7 sequential use in the treatment of cancer, 8 wherein said chemotherapeutic agent is a 9 topoisomerase inhibitor or a thymidylate 10 synthase inhibitor, and wherein the cancer 11 cells comprise a p53 mutation. 12

13

A pharmaceutical composition characterised by 14 19. the presence of a p53 mutation, wherein the 15 composition comprises a) a specific binding 16 . member which binds to a cell death receptor or 17 a nucleic acid encoding said binding member and 18 (b) a chemotherapeutic agent, wherein said 19 chemotherapeutic agent is a topoisomerase 20 inhibitor or a thymidylate synthase inhibitor 21 and (c) a pharmaceutically acceptable 22 excipient, diluent or carrier... 23

24

25 20. The product according to claim 18 or the
26 pharmaceutical composition according to claim
27 19 wherein the cancer is one or more of
28 colorectal, breast, ovarian, cervical,
29 gastric, lung, liver, skin and myeloid (e.g.
30 bone marrow) cancer.

31

WO 2005/053739 PCT/GB2004/005008

The product according to claim 18 or claim 20 1 21. or the pharmaceutical composition according to 2 claim 19 or claim 20 wherein the binding member 3 is an antibody or a fragment thereof. 4 5 The product according to claim 18 or claim 20 22. 6 or 21 or the pharmaceutical composition 7 according to claim 19 or claim 20 or 21 wherein 8 the death receptor is FAS. 9 10 The product according to claim 18 or any one of 23. 11 claims 20 to 22 or the pharmaceutical 12 composition according to claim 19 or or any one 13 of claims 20 to 22 wherein the binding member 14 is the anti-FAS antibody CH11. 15 16 The product according to claim 18 or any one of 17 24. claims 20 to 23 or the pharmaceutical 18 composition according to claim 19 or or any one 19 of claims 20 to 23 wherein said 20 chemotherapeutic agent is an antifolate 21 thymidylate synthase inhibitor or a 22 topoisomerase-I inhibitor. 23 24 The product according to claim 18 or any one of 25. 25 claims 20 to 24 or the pharmaceutical 26 composition according to claim 19 or or any one 27 of claims 20 to 24, wherein said 28 chemotherapeutic agent is TDX or irinotecan 29 (CPT-11). 30

31

80

WO 2005/053739

26. The product or pharmaceutical composition 1 2 according to claim 25 wherein said specific binding member and chemotherapeutic agent are 3 provided in concentrations sufficient to 4 produce an RI of greater than 1.5. 5 6 7 27. A kit for the treatment of a cancer characterised by the presence of a p53 8 mutation, said kit comprising a) a specific 9 binding member which binds to a cell death 10 receptor or a nucleic acid encoding said 11 12 binding member and (b) a chemotherapeutic agent, wherein said chemotherapeutic agent is a 13 14 topoisomerase inhibitor or a thymidylate synthase inhibitor and (c) instructions for the 15 16 administration of (a) and (b) separately, 17 sequentially or simultaneously. 18 19 20

PCT/GB2004/005008